Joel Mawdsley
Overview
Explore the profile of Joel Mawdsley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meade S, Routledge E, Sharma E, Honap S, Zeki S, Ray S, et al.
Frontline Gastroenterol
. 2023 Jul;
14(4):312-318.
PMID: 37409343
Objective: The second iteration of the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) initiative recommends use of the Simple Endoscopic Score for Crohn's disease (SES-CD) as a treatment target...
2.
Joshi S, Mawdsley J, Hullah E, Ormond M, Carey B
Br J Hosp Med (Lond)
. 2023 Mar;
29(3):1-16.
PMID: 36989148
Orofacial granulomatosis is a chronic relapsing-remitting inflammatory condition that shares a similar phenotypic presentation to some other granulomatous diseases, particularly Crohn's disease. However, subtle clinical and pathological differences justify it...
3.
Meade S, Patel K, Luber R, OHanlon D, Caracostea A, Pavlidis P, et al.
Aliment Pharmacol Ther
. 2022 Jun;
56(4):646-663.
PMID: 35723622
Background: Low-quality evidence suggests that pre-operative exclusive enteral nutrition (E/EN) can improve postoperative outcomes in patients with Crohn's disease (CD). It is not standard practice in most centres. Aims: To...
4.
Luber R, Duff A, Pavlidis P, Honap S, Meade S, Ray S, et al.
JGH Open
. 2022 Jan;
6(1):76-84.
PMID: 35071792
Background And Aim: Patients with chronic diseases are believed to be at increased risk of mental health conditions during the COVID-19 pandemic. We aimed to assess the incidence of psychological...
5.
Luber R, ONeill R, Singh S, Sharma E, Cunningham G, Honap S, et al.
Aliment Pharmacol Ther
. 2021 Jul;
54(5):678-688.
PMID: 34223654
Background: Biologics account for a significant cost in inflammatory bowel disease (IBD) management; however, switching from infliximab originator to its biosimilars has enabled cost saving without compromising disease control. The...
6.
Sharma E, Meade S, DErrico F, Pavlidis P, Luber R, Zeki S, et al.
GastroHep
. 2020 Dec;
2(6):318-326.
PMID: 33362435
Background: To quantify the effects of COVID-19 on our inflammatory bowel disease (IBD) unit, including service provision, prescribing practices and use of therapeutic drug monitoring (TDM). Methods: We performed a...
7.
Kennedy N, Hansen R, Younge L, Mawdsley J, Beattie R, Din S, et al.
Frontline Gastroenterol
. 2020 Sep;
11(5):343-350.
PMID: 32874484
Objective: To determine the challenges in diagnosis, monitoring, support provision in the management of inflammatory bowel disease (IBD) patients and explore the adaptations of IBD services. Methods: Internet-based survey by...
8.
Honap S, Pavlidis P, Ray S, Sharma E, Anderson S, Sanderson J, et al.
Inflamm Bowel Dis
. 2020 Jun;
26(11):e147-e149.
PMID: 32566937
No abstract available.
9.
Samaan M, Cunningham G, Tamilarasan A, Beltran L, Pavlidis P, Ray S, et al.
Aliment Pharmacol Ther
. 2020 Jun;
52(2):292-302.
PMID: 32506695
Background: Significant associations between serum golimumab concentrations and favourable outcomes have been observed during both induction and maintenance therapy in ulcerative colitis (UC). However, data regarding optimal therapeutic serum golimumab...
10.
Samaan M, Birdi S, Morales M, Honap S, Tamilarasan A, Cunningham G, et al.
Frontline Gastroenterol
. 2020 May;
11(3):188-193.
PMID: 32419909
Background: Despite the proven efficacy of vedolizumab (VDZ) for ulcerative colitis (UC) and Crohn's disease (CD), suboptimal response is commonly encountered. However, data regarding the effectiveness of dose intensification (by...